ATAGI approves Pfizer for 5 to 11 year-olds

ATAGI recommendations on the use of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years in Australia

Key Points

• The Therapeutic Goods Administration (TGA) has approved the Pfizer COVID-19 vaccine for children who are 5 to 11 years of age.
• The Australian Technical Advisory Group on Immunisation (ATAGI) has approved the use of the Pfizer COVID-19 vaccine in children aged 5 to 11 years.
• The recommended schedule for vaccination in this age group is 2 doses, 8 weeks apart. The interval can be shortened in special circumstances to a minimum of 3 weeks, such as in an outbreak response, prior to the initiation of significant immunosuppression or international travel.
• Children who turn 12 after their first dose may receive the adolescent/adult formation of the Pfizer COVID-19 vaccine to complete their primary vaccine course.
• The Pfizer COVID-19 vaccine is expected to be available for this group in January.

More Details

CLICK HERE